心胸外科术后新发持续性阿片类药物使用与处方量的关系
该研究基于2009至2015年接受心胸外科手术的医保患者数据,分析围术期阿片处方量与术后新发持续性阿片使用的关系。结果显示,处方量是术后新发持续使用的最强预测因素之一。
要点
- 心胸外科术后新发持续性阿片使用率为12.8%,且逐年下降
- 处方量超过450 OME者调整后新发持续使用率高于200 OME及以下者
- 围术期阿片处方的大小和时机是可干预的重点风险因素
核心结论
- 围术期阿片处方的大小和时机是心胸外科术后新发持续性阿片使用的最强预测因素,处方量等可干预因素应作为降低新发持续使用的目标。
研究设计与样本
- 回顾性队列研究,纳入2009至2015年接受心胸外科手术的医保患者24549例,均为阿片未暴露者,且术前30天至出院后14天内有阿片处方填充、术前12个月及术后6个月医保连续参保。
主要发现
- 总体新发持续性阿片使用率为12.8%(24549例中3153例),从2009年的17%逐年下降至2015年的7.1%(P < .001)。
- 处方量超过450 OME者调整后新发持续使用率为19.6%(95%CI 18.7%~20.4%),高于200 OME及以下者的10.4%(95%CI 9.9%~10.8%)(P < .001)。
- 与之一致的关联因素包括术前处方记录、黑人种族、胃肠并发症、残疾状态、开胸肺切除、双重资格、药物和物质滥用、女性、吸烟、高共病、疼痛障碍、较长住院时间和较年轻年龄。
关键数值与推荐
- 新发持续性使用定义为术后91至180天持续有处方记录,处方量以口服吗啡当量(OME)表示。
临床怎么用
- 在心胸外科围术期应关注阿片处方量与时机的管理,针对可干预的处方因素采取干预以降低术后新发持续性阿片使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New persistent opioid use occurs in 3% to 14% of patients after elective surgery, but is poorly described after cardiothoracic surgery. We examined the association of prescription size with new persistent opioid use after cardiothoracic surgery. METHODS: Opioid-naive Medicare patients undergoing cardiothoracic surgery between 2009 and 2015 were identified. Patients who filled an opioid prescription between 30 days before surgery and 14 days after discharge and with continuous Medicare enrollment 12 months before and 6 months after surgery were selected (n = 24,549). New persistent use was defined as continued prescription fills 91 to 180 days after surgery. Prescription size was reported in oral morphine equivalents. Multivariable regression was performed for risk adjustment, and new persistent use rate was estimated. RESULTS: Patient age was 71 ± 8 years, 9222 (38%) were female, and 20,898 (85%) were white. Overall new persistent use was 12.8% (3153 of 24,549), and declined yearly from 17% in 2009 to 7.1% in 2015 (P < .001). Prescription size, preoperative prescription fills, black race, gastrointestinal complications, disability status, open lung resection, dual eligibility (Medicare and Medicaid), drug and substance abuse, female sex, tobacco use, high comorbidity, pain disorders, longer hospital stay, and younger age were associated with new persistent use. Adjusted new persistent use was 19.6% (95% confidence interval, 18.7% to 20.4%) among patients prescribed more than 450 oral morphine equivalents, compared with 10.4% (95% confidence interval, 9.9% to 10.8%) among those prescribed 200 oral morphine equivalents or less (P < .001). CONCLUSIONS: Size and timing of perioperative opioid prescriptions were the strongest predictors of new persistent opioid use after cardiothoracic surgery. Modifiable risk factors such as prescription size should be targeted to reduce new persistent use.
引用
- Brescia AA, Waljee JF, Hu HM, et al. Impact of Prescribing on New Persistent Opioid Use After Cardiothoracic Surgery. Ann Thorac Surg. 2019. PMID: 31447051. doi:10.1016/j.athoracsur.2019.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。